Mephenytoin metabolism

De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994 46 594-598. 

Balian JD, Sukhova N, Harris JW, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism a population study. Clin Pharmacol Ther 1995 57 662-669. 

Goldstein JA, Blaisdell J. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. In Johnson EF, Waterman MR, eds. Cytochrome P450, Part B Methods in Enzy-mology. San Diego, CA Academic Press, 1996 272 210-218. 

The mephenytoin metabolic pathway is utilized by commonly used drugs, such as mephobarbital, hexobarbital, diazepam, imipramine and omepra-zol, but only 3-5% of Caucasians and 8% of Blacks are poor metabolizers of mephenytoin, compared to 15-20% of Chinese and Japanese populations (Kupfer et al., 1988). This enzyme s activity is inhibited by floconazole and fluoxetine and induced by drugs such as barbiturates and nicotine (smoking). 

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.Biol. Chem. 269, 15419-15422. 

Balian, J.D. Sukhova, N. Harris, J.W. Hewett, J. Pickle, L. Goldstein, J.A. Woosley, R.L. Flockhart, D.A. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism A population study. Clin.Pharmacol.Ther., 1995, 57, 662-669... 

---